Bio-Techne (TECH) shares ended the last trading session 10.8% higher at $54.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.5% loss over the past four weeks.Bio-Techne scored a strong price increase on investors’ optimism surrounding its impending fiscal 2025 third-quarter financial results, expected to release on May 7 before the opening bell. In the last reported second quarter, both the top and bottom lin ...

Company Overview - CMB.TECH is a diversified maritime group that owns and operates over 150 seagoing vessels, including crude oil tankers, dry bulk vessels, container ships, chemical tankers, offshore wind vessels, and workboats [3] - The company also provides hydrogen and ammonia fuel to customers, sourced from its own production or third-party producers [3] - CMB.TECH is headquartered in Antwerp, Belgium, with offices across Europe, Asia, the United States, and Africa [3] Financial Reporting - CMB.TECH published its annual report for the year ended December 31, 2024, in accordance with Belgian law, available on its website [1] - The annual report on Form 20-F was submitted to the U.S. Securities and Exchange Commission on April 9, 2025, and can be downloaded from the company's website [2] Stock Information - CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol CMBT [4]

MINNEAPOLIS, April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and protease-free workflows on Leica's BOND RX research staining instrument, further advancing the capabilities of spati ...

Bio-Techne Corporation (TECH) recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa ("EMEA") region. The facility's capacity should enable the company to grow its customer-centric team in the EMEA and support long-term regional growth. Latest Updates From Bio-Techne's Peers In the life sciences research space, Bio-Techne faces competition from some prominent MedTech players. These companies are also making notable developments i ...

Core Insights - Bio-Techne Corporation is opening a new Customer Experience Centre in Düsseldorf, Germany, aimed at enhancing customer engagement across the EMEA region and supporting long-term growth strategies [1][2] - The new facility will feature a state-of-the-art Demonstration Laboratory showcasing Bio-Techne's full instrument portfolio, allowing customers to gain hands-on experience [1] - Düsseldorf was selected for its strong life sciences sector and strategic location, facilitating access to multiple European markets [2] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [3] - The company employs around 3,100 people worldwide and offers a wide range of products that assist in scientific investigations and drug discovery [3] - Recent product innovations include the Leo™ System, which automates western blot assays, and the COMET™ platform, known for its high-throughput tissue profiling capabilities [4]

MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagn ...

Bio-Techne Corporation (TECH) recently began shipping the Leo System, powered by Simple Western Technology. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.Leo will enable Bio-Techne’s customers to accelerate their cutting-edge science and bring next-generation therapies to market faster. TECH Stock Likely to Gain From the DevelopmentSince the announcement on March 1 ...

MINNEAPOLIS, March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot as ...

Core Viewpoint - CMB.TECH NV has announced the acquisition of approximately 40.4% of Golden Ocean Group Limited's issued share capital through its subsidiary, marking a significant step in its diversification strategy [1][2][3] Group 1: Acquisition Details - CMB.TECH is acquiring 81,363,730 shares of Golden Ocean at a price of 14.49 USD per share, totaling approximately 1.18 billion USD [1] - The shares represent about 40.4% of Golden Ocean's issued share capital and approximately 40.8% of its outstanding shares with voting rights [1] - The transaction is expected to complete on 12 March 2025 and is not subject to any conditions [4] Group 2: Strategic Intent - The acquisition aligns with CMB.TECH's strategic objective of diversification, aiming to become a long-term shareholder in Golden Ocean and invest in a modern dry bulk fleet [2] - CEO Alexander Saverys emphasized the importance of this acquisition as a milestone in the company's diversification strategy and expressed intentions to engage with Golden Ocean's management to drive long-term growth and innovation [3] Group 3: Financial Considerations - CMB.TECH has identified a bank syndicate to refinance all or parts of Golden Ocean's current outstanding debt, indicating proactive financial management in light of the acquisition [4]

Core Viewpoint - Bio-Techne Corporation's partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit is expected to enhance its Diagnostics and Spatial Biology segment, despite a recent dip in stock price [1][2][3]. Company Developments - The AmplideX Nanopore Carrier Plus Kit is a new genetic panel designed for carrier screening research, providing a streamlined method for comprehensive sequencing data [1][6]. - Asuragen, a Bio-Techne brand, is recognized for high-quality molecular diagnostic products, and the partnership is anticipated to improve market sentiment towards Bio-Techne's stock [3]. - Bio-Techne has a market capitalization of $9.76 billion, with a Zacks Consensus Estimate indicating a 6.8% year-over-year increase in fiscal 2025 earnings and a 5.5% revenue improvement [4]. Product Significance - The AmplideX Nanopore Carrier Plus Kit addresses the updated ACMG recommendations for carrier screening, allowing for the analysis of genes not detectable by standard short-read sequencing [5]. - The kit includes a panel of 11 genes, such as CFTR and CYP21A2, which are prevalent but challenging to detect with traditional methods [6][7]. Industry Prospects - The global Nanopore Sequencing market is projected to grow from $330.59 million in 2023 to a compound annual growth rate (CAGR) of 18.07% through 2029, driven by increasing demand for DNA sequencing and technological advancements [8].